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Dr William Quinones-Baldrich (Los Angeles, Calif): This is
a review of events occurring after 30 days of implantation of the
Zenith aortic endograft for the treatment of infrarenal abdominal
aortic aneurysms. The authors report an incidence of type II
endoleak of 5.8%, which is quite low, and no type I endoleaks.
Similarly, graft occlusions were rare, only one requiring surgical
treatment with a femorofemoral bypass. The authors also find that
hypertensive patients with type II endoleaks more often require
intervention for increase in the size of the aneurysm. The latter is
an important finding as it strongly suggests that in the presence of
a type II endoleak, blood pressure control is of benefit.
The authors also conclude that routine follow-up imaging
plays a limited role in the identification and prevention of graft
failure. They now recommend CT scan without contrast, noting
that the size of the aneurysm and detection of migration are the
most important factors during follow-up. Several reports are not-
ing a gradual decrease in renal function in patients treated with
endovascular grafts regardless of whether or not suprarenal fixation
is present. Therefore, avoiding contrast during follow-up in these
patients is important.
The occurrence of type III endoleaks leads the authors to
increase the degree of intercomponent overlap to a minimum of
1½ stents. Their experience with graft limb occlusion has led them
to be more aggressive in placing stents in areas of concern at the
time of implantation. These are excellent recommendations based
on the authors’ extensive experience with this device.
Unfortunately, this report only presents part of the picture. By
omitting events during the first 30 days of follow-up, the incidence
of postimplantation events is underestimated. In the manuscript, it
is clear that several type I endoleaks were treated with proximal
extensions, some limb occlusions were treated with thrombolysis
and stent placement, and some type III endoleaks were also
detected. They have also observed stent fractures, barb separation,
and top stent separation. The latter events are more likely to have
occurred after 30 days. I have several questions for the authors.
During follow-up you found that women tend to have more
events than men. My first question is why are there so few women
in your cohort? Does gender influence your recommendations?
Even though it is not the emphasis of your presentation today,
could you give us information on events occurring in the first 30
days? What is the overall incidence of type I, II, and III endoleaks
in your experience? When and how often were the stent fractures,
bar and/or stent separation observed? Do you have information on
long-term renal function in patients receiving the Zenith endograft
for treatment of their abdominal aortic aneurysms? And finally, inif everything looks well, I will then alternate duplex scan and CT
during the follow-up. Have you had any experience using duplex
scan for follow-up?
I congratulate the authors on an excellent experience and
thank you for providing me a copy of the manuscript in advance of
the meeting. I also wish to thank the society for the privilege of
discussing this paper.
Dr JadeHiramoto: Thank you, Dr Quinones. With regard to
your first question, we did not alter our recommendations for
treatment based on gender. We did have very few women in our
study. Part of this may be explained by the fact that a large
proportion of our operations were performed at the VA, where
essentially all of the patients are men. Gender may initially have
played a role in our recommendations when we were worried that
because of access issues they might not be appropriate candidates;
however, we use the same anatomic criteria for all patients. We do
not take gender into consideration now. We look at the diameters
of our access vessels andmake appropriate recommendations based
on those size measurements.
Women did tend to do worse in terms of late graft failure.
They were also more likely to require treatment for their type II
endoleaks, and if you actually look at all interventions—early
complications, late complications, treatment of type II en-
doleaks—it is statistically significant. It did not reach statistical
significance when you just looked at each of these separately, but if
you pooled all interventions they (women) did worse. I think it is
difficult to explain. The women tended to be older on presentation
for their aneurysm repair, but there did not appear to be an
interaction between age and gender. Gender itself was an indepen-
dent predictor.
Again, this talk was really devoted towards looking at the
long-term complications since this device has been in use since
1998 at UCSF, and we wanted to analyze and present our long-
term data. However, with regards to complications fromwithin the
first 30 days, there were a total of 10, for an overall late and early
complication rate of 19 in the entire cohort. The majority of the
early complications, as you might imagine, were limb thromboses.
It was probably 7 out of those 10. There were probably 1 or 2 type
I endoleaks and no treated type II endoleaks in the first 30 days.
With regards to stent fracture, barb fractures, and stent sepa-
ration, there has been a total of four in our series and they have not
required treatment. They have been recognized on the follow-up
abdominal x-rays and followed but not treated.
In terms of the long-term renal function of these patients, I do
not have all of their data analyzed at this point to determine the
number of patients who have had worsening renal function or
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our data. I do have their preoperative values, and there was quite a
range, but the average preoperative creatinine was 1.2. With re-
gards to duplex ultrasound, I think that it is an excellent imaging
modality. I think in the face of going to noncontrast CT scans if the
1-month postoperative contrast-enhanced CT does not demon-
strate enlargement of the aneurysm or an endoleak, I think a
duplex would be a great adjunctive measure to include. This would
be especially useful in a patient who maybe has some renal insuffi-
ciency, gets a noncontrast CT scan, and there is a question of
aneurysm sac enlargement; perhaps a duplex would be useful in
that patient to determine if they have evidence of an endoleak.
8. “Late Complications After Endovascular Aneurysm Repair
Using the Zenith Stent Graft.” Discussion by Benjamin Starnes,
Tacoma, WA.
DrBenjamin Starnes (Tacoma,Wash): I congratulate you on
a very impressive experience. One of the unique aspects, and in my
opinion, one of the favorable aspects of the Zenith system is that
however, postoperative imaging should clearly be performed. Thethe main body is sized all the way down to the aortic bifurcation
and this theoretically assists in preventing distal migration. You had
one case where the renal artery was occluded, you presumed,
because of overlap of the orifice of the renal artery. I am wonder-
ing, because I have had one similar case, have you ever seen any
instance of proximal migration of the graft after aneurysm remod-
eling, especially in very large aortic aneurysms?
DrHiramoto:Not tomy knowledge, and certainly not in this
series of patients. This one case of renal artery occlusion that we
presented today was clearly an intraoperative event that was not
recognized at the time of the procedure. Looking back at the
intraoperative angiogram, you see that the top of the covered
portion of the stent graft was almost completely covering that renal
artery. This was the only patient in which that occurred, and again,
I think this was an early mistake that was recognized late. This was
not a case of proximal migration, nor have we observed proximal
migration in this series of patients.INVITED COMMENTARYMark F. Fillinger, MD, Lebanon, NH
I enjoyed reading this article, which is important because of its
size and length of follow-up (at least 3 years in 121 of 325
patients). The clinical results are excellent, with a low rate of
reintervention and aneurysm-related death beyond 30 days. That
being said, the follow-up is primarily from 30 days to 5 years,
defined as “mid-term” by Society for Vascular Surgery reporting
standards,1 and should be taken in that context.
I was initially taken aback when I read that “Large prospec-
tive studies and registries have failed to produce the kind of
device specific data. . .needed for informed decisions on patient
selection, device selection, and follow-up.” I suspect the authors
of the DREAM, EVAR, EUROSTAR, and other studies would
take issue with that comment.2-5 Nonetheless, I think Hiramoto et
al are pointing out that a large single-center study can bring a
unique perspective when it combines consistency in evaluation and
follow-up with access to the patient’s chart and raw imaging data.
Of course, this unique perspective can lead to bias, but it can also
provide unique insights.
Most of the insights in this paper have a sound basis in fact, as
well as some controversy: (1) The Zenith device has very good
mid-term results, consistent with EUROSTAR, clinical trials, and
other studies. I will avoid discussing the “barbs” regarding other
devices, as this is not a concurrent comparative study including
other devices. (2) Opinions regarding intervention for type II
endoleak are changing. I would like to have seen more information
about how often the treatment of endoleak was successful in
stopping the endoleak or resolving aneurysm enlargement, as this
would have helped influence decision-making regarding follow-up
and intervention. (3) When a device has a low rate of failures and
reinterventions, any imagingmodality will have a low yield. Even at
an intervention rate of 8.5% over an average 2.3 years’ follow-up,authors make a good point that if there is no endoleak on initial
computed tomography, if there is no migration of components,
and if the aneurysm is shrinking, no contrast should be needed on
future computed tomography for a device with this track record.
Noncontrast computed tomography provides good information
about migration, deformation, aneurysm sac size, and, in some
cases, fracture (the only missing parameter is endoleak). This
article should not be used as an excuse to avoid imaging studies,
nor do the authors suggest that.
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